Key result
ANLN overexpression links to tumor progression and treatment resistance, emerging as a promising biomarker and target.
Why the study?
ANLN is aberrantly overexpressed in various cancers and contributes to treatment resistance, emerging as a promising prognostic biomarker and potential therapeutic target.
ANLN is a highly conserved actin-binding protein that is overexpressed in multiple cancers and contributes to tumor progression and treatment resistance, making it a potential prognostic biomarker and therapeutic target.
ANLN is a highly conserved actin-binding protein that plays a critical role in cytokinesis by interacting with key cytoskeletal components such as actin, myosin, and RhoA. Increasing evidence shows that ANLN is aberrantly overexpressed in various cancers, including lung, breast, and liver cancers, and that its elevated expression is associated with enhanced tumor cell proliferation, migration, and invasion. Because of its central involvement in tumorigenesis and disease progression, ANLN has emerged as a promising prognostic biomarker and potential therapeutic target. Recent studies have demonstrated that ANLN contributes to resistance to chemotherapy, targeted therapy, and immunotherapy through multiple molecular mechanisms. This review provides a systematic overview of the physiological functions of ANLN, its roles in cancer initiation and progression, and its regulatory mechanisms in treatment resistance, offering biological insights into precision oncology and potential strategies for overcoming therapeutic resistance in cancer.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a review in Malignant tumors. ANLN is aberrantly overexpressed in various cancers and contributes to tumor progression and treatment resistance, emerging as a promising prognostic biomarker and therapeutic target.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: